PYRAMID-1
03 Jan 2023
Trial Summary
This is a randomized, positive-controlled, open-label, international multicenter, Phase 3 clinical study to compare the efficacy and safety of pyrotinib versus docetaxel in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.
Acronym:
PYRAMID-1
ACTRN/NCT /ethics:
NCT04447118
Scientific title:
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
Sponsor / Cooperative group:
Jiangsu HengRui Medicine Co., Ltd.
Trial & Patient Characteristics
| Cancer Type | Lung |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced: Metastatic or Widespread |
| Anticipated Start Date | 2020-09-11 |
| Anticipated End Date | 2023-10-31 |
Participating Hospitals
| Hospital | Calvary North Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Julie Rowe |
| julie.rowe@calvarycare.org.au | |
| Phone | 08 8239 9536 |
| Principal Investigator | Dr Rohit Joshi |
| Recruitment Status | Recruiting |